Latest Breaking News On - Alexab kimball - Page 7 : comparemela.com

Phase 3 Trial Data on Bimekizumab for Patients with Hidradenitis Suppurativa

New late-breaking data showed positive results for bimekizumab treatment of hidradenitis suppurativa, with higher response rates and a strong safety profile.

United statesAlexab kimballAmerican academy of dermatologyBeth israel deaconess medical centerDrug administrationHarvard medical schoolAmerican academyNew orleansBeth israel deaconess medical

Studies Validate IL-17 as Hidradenitis Suppurativa Drug Target

Two phase 3 studies with the IL-17 inhibitor bimekizumab for moderate-to-severe hidradenitis suppurativa generate clinically meaningful results, researchers report.

United statesChristopherj sayedAlexab kimballAmerican academy of dermatologyBeth israel deaconess medical centerResearch sessionHarvard medical schoolUniversity of north carolinaAmerican academyHidradenitis suppurativa clinical responseDermatology life quality indexNorth carolinaChapel hillSkin and soft tissue infectionHumanized monoclonal antibodyHidradenitis suppurativa

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Bruxelles capitaleUnited statesUnited kingdomGreat britainClin pharmacolRelationsantje witteImmunologynicole hergaHidradenitis suppurativaAlexab kimballImmunology solutionsUs communicationsAmerican academy of dermatology annual meetingDrug administrationEuropean union eu economic areaAmerican academyAnnual meeting

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

Patients treated with investigational bimekizumab, an IL-17A and IL-17F inhibitor, achieved statistically significant and clinically meaningful improvements.

Bruxelles capitaleUnited statesUnited kingdomGreat britainNicole hergaClin pharmacolHidradenitis suppurativaAlexab kimballImmunology solutionsUs communicationsAmerican academy of dermatology annual meetingDrug administrationEuropean union eu economic areaAmerican academyAnnual meetingNew orleans